Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pasotuxizumab
- Development stage
- Phase 1
- Lead developer
- Amgen
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
Pasotuxizumab (BAY 2010112) is a bispecific T-cell engager (BiTE) antibody construct developed for the treatment of prostate cancer. It consists of two single-chain variable fragments (scFvs) joined by a flexible linker; one scFv binds to the Prostate-Specific Membrane Antigen (PSMA) expressed on the surface of prostate cancer cells, while the other binds to the CD3 epsilon subunit of the T-cell receptor complex. By cross-linking these two targets, pasotuxizumab brings cytotoxic T-cells into direct contact with tumor cells, bypassing the need for major histocompatibility complex (MHC) class I recognition and leading to targeted tumor cell death. Originally developed by Micromet (later Amgen) as AMG 212, it was licensed to Bayer for clinical development. Although it showed clinical activity in Phase I trials for metastatic castration-resistant prostate cancer (mCRPC), development was eventually terminated by Bayer for business reasons.
- Other names
- pasotuxizumabPSMA BiTE
02
Targets
PSMA (Prostate-specific membrane antigen)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on pasotuxizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pasotuxizumab.